In December, PersonGen won the " Deep Cultivation Award of Cell Therapy Enterprise ".

In December, PersonGen was awarded the "Listed Nursery Enterprise".

In December, PersonGen has built a Clinical-Grade Lentivirus Suspension Preparation Technology Platform.

In December, PersonGen announced the Clearance of IND Application of CD19-CAR-T by CDE.

In November, PersonGen won the National High-Tech Enterprise.

In September, PersonGen's autologous CD7-CAR-T achieved a major breakthrough.

In June, PersonGen's CD7-CAR-NK achieved a major progress.

In April, Dr. Lin YANG was awarded the "Leading Entrepreneurial Talent" in Hefei City.

In March, PersonGen participated in the cooperative development of key research and development projects in Anhui Province.

In March, Dr. Yang Lin won the " Award of Excellent Paper ".

In February, PersonGen has achieved major clinical progress in CD19-CAR-T and BCMA-CAR-T cell products.